Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NHERF1 | O14745 | 3/20 | 0.38 |
| ▸ | PLCG2 | P16885 | 1/20 | 0.37 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.36 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.35 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.35 |
| ▸ | PYGL | P06737 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6711899 | 0.91 | HIF1A (0.36) | MAP3K5EGFRPIK3CANSD2 | |
| SCHEMBL6709889 | 0.89 | MAPT (0.43) | — | |
| SCHEMBL6707893 | 0.89 | HDAC1 (0.35) | MAP3K5EGFRPIK3CANSD2TP53 | |
| SCHEMBL6713754 | 0.89 | SERPINE1 (0.43) | NHERF1PLCG2NSD2STK33 | |
| SCHEMBL6712529 | 0.88 | CASP3 (0.39) | NHERF1PLCG2PTK2BMAP3K5NSD2 | |
| SCHEMBL6710125 | 0.86 | SERPINE1 (0.48) | NHERF1PLCG2STK33 | |
| SCHEMBL6711906 | 0.86 | NHERF1 (0.46) | NHERF1PLCG2EGFRPIK3CASTK33 | |
| SCHEMBL6713158 | 0.86 | MAPT (0.39) | NHERF1PLCG2PTK2BMAP3K5NSD2 | |
| SCHEMBL6710112 | 0.85 | MAP3K5 (0.45) | NHERF1PLCG2PTK2BMAP3K5NSD2 | |
| SCHEMBL6708643 | 0.85 | MAPT (0.41) | NHERF1PLCG2PTK2BMAP3K5NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | NHERF1 1641/4885PLCG2 4289/4885PTK2B 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.